Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696127332,"tweetId":"696127332","gmtCreate":1640652947747,"gmtModify":1640652947992,"author":{"id":4087524360121530,"idStr":"4087524360121530","authorId":4087524360121530,"authorIdStr":"4087524360121530","name":"JoeKun","avatar":"https://static.tigerbbs.com/a543b7a138549431b97b6bee2bc9e956","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696127332","repostId":1156481741,"repostType":4,"repost":{"id":"1156481741","kind":"news","pubTimestamp":1640652473,"share":"https://www.laohu8.com/m/news/1156481741?lang=zh_CN&edition=full","pubTime":"2021-12-28 08:47","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA批准默克公司的新冠药物后，默克公司的股票是买入还是卖出？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481741","media":"Investors","summary":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Me","content":"The Food and Drug Administration authorized&nbsp;Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.<blockquote>食品药品监督管理局授权默克(MRK)的抗病毒新冠药物莫努匹拉韦。但默克股票仍面临压力。</blockquote> The FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.<blockquote>FDA授权Ridgeback Biotherapeutics合作的药丸在其他选择不可用或不合适时紧急使用。辉瑞(PFE)的两片疗法Paxlovid也获得了授权。Paxlovid在临床测试中被证明更有效。此外，molnupiravir具有癌症风险，并可能导致未出生儿童的出生缺陷。</blockquote> Merck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.<blockquote>当患者在症状出现后五天内开始治疗时，默克公司的molnupiravir将与Covid相关的住院或死亡风险降低了30%。对于症状出现后三天内开始治疗的患者，Paxlovid将相同的风险降低了89%。</blockquote> Merck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.<blockquote>默克股价远低于11月份达到的高点。乐观的是，该公司超出了第三季度的预期，并提供了乐观的2021年前景，其中不包括抗病毒药物的潜在影响。Molnupiravir在英国和日本也被允许。</blockquote> Merck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.<blockquote>默沙东预计今年将生产1000万个疗程的molnupiravir，2022年至少生产2000万个疗程。它与包括美国在内的全球30多个国家签订了供应协议。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售额最高</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益增长28%至每股1.75美元，销售额飙升20%至131.5亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导欧加农（OGN）分拆。该制药公司将全年调整后利润预期上调至每股5.65美元至5.70美元，销售额为474亿美元至479亿美元。两项指标均超出预期。而且它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物Keytruda。Keytruda占第三季度总销售额的三分之一以上。Keytruda销售额增长22%，达到45.3亿美元。其人乳头瘤病毒疫苗Gardasil的销售额飙升68%，达到19.9亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物Januvia的收入下降了1%，至13.4亿美元。默克公司报告称，由于新冠疫苗在美国占据优先地位，其肺炎疫苗Pneumovax 23的销量下降了26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合CAN SLIM投资规则，该规则建议投资者寻找近期季度增长率为20%-25%或更高的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.<blockquote>FactSet调查的分析师预计默克本季度每股收益为1.52美元，销售额为131.6亿美元。与去年同期相比，盈利将飙升约21%，销售额将增长5%以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标对默克有何影响？</blockquote> As Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至12月27日，默克股价年内小幅下跌。股价最近创下至少三年来的新高，但此后一直在下跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克的销售额增长了2.5%，达到479.9亿美元。这一增长率较2019年11%的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.<blockquote>分析师预计2021年销售额将小幅增长至484.4亿美元。收入预计将增长2.8%，达到每股5.82美元。此前，2020年将增长14%。</blockquote> The stock ranks 6th by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业中的综合评级排名第六。由33家公司组成的医德药品集团在《投资者商报》追踪的197家集团中排名第51位。</blockquote> Technical Analysis Of The Pharmaceutical Company<blockquote>制药公司的技术分析</blockquote> Merck stock has a&nbsp;Composite Rating&nbsp;of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.<blockquote>默克股票的综合评级为81分（满分为99分）。CR是衡量股票过去12个月关键增长指标的指标。这使得默克股票在所有股票中排名前19%，无论行业类别如何。</blockquote> Shares also have a&nbsp;Relative Strength Rating&nbsp;of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.<blockquote>股票的相对强度评级也为57，反映了默克股票12个月的表现。这意味着该医药股的业绩排名低于所有股票的前三分之一。</blockquote> It's also key to watch chart patterns. Merck stock broke out of a&nbsp;flat base&nbsp;with abuy point&nbsp;at 79.33 on Oct. 1, according to&nbsp;MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are&nbsp;encouraged to sell&nbsp;when a stock is 7%-8% below its entry.<blockquote>观察图表模式也很关键。根据MarketSmith.com的数据，默克股价在10月1日突破了一个平盘，买入点为79.33点。但股价较11月30日入场时下跌了7%。这触发了卖出信号。当股票比进场价低7%-8%时，鼓励投资者卖出。</blockquote> Merck stock also recently undercut its&nbsp;50-day&nbsp;and&nbsp;200-day&nbsp;moving averages. Both are sell signals.<blockquote>默克股票最近也跌破了50日和200日移动平均线。两者都是卖出信号。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠协议</blockquote> Merck's molnupiravir is now authorized in the U.S., U.K. and Japan.<blockquote>默克公司的molnupiravir现已在美国、英国和日本获得授权。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药公司（AVIR）和Enanta制药(ENTA)正在研究口服新冠药物。罗氏(RHHBY)最近退出了与Atea的Covid抗病毒药物交易。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析师表示，与抗体药物相比，这些药物可能为新冠病毒的非住院治疗提供更容易的途径再生元制药（REGN），礼来公司（LLY）及维尔生物技术（来）。抗体药物必须由卫生保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心莫努匹拉韦的作用方式可能会给未出生婴儿的DNA带来突变。因此，FDA顾问对是否推荐孕妇使用它犹豫不决。</blockquote> Bearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and&nbsp;Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.<blockquote>悲观的是，FDA暂停了一项测试艾滋病毒预防药物islatravir的研究。一些患者显示关键免疫细胞减少。默克和吉利德科学（GILD）也决定停止在HIV患者中测试islatravir和吉利德的lenacapavir的一种方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克最近也完成了对Acceleron的收购。</blockquote> In early March, President Joe Biden announced Merck would helpJohnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克公司将提供帮助强生公司(JNJ)生产其新冠疫苗。默克公司将从生物医学高级研究与发展局获得2.688亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据CAN SLIM投资规则，不，默克股票目前不值得买入。股价已经反复突破了之前的突破，并引发了多个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利都可能低于预期。预计本季度的销售额不会达到这一目标。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大型股票可以在不实现大幅增长的情况下增加涨幅。</blockquote>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA批准默克公司的新冠药物后，默克公司的股票是买入还是卖出？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA批准默克公司的新冠药物后，默克公司的股票是买入还是卖出？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nInvestors2021-12-28 08:47\n\n</h4>\n</header>\n<article>\nThe Food and Drug Administration authorized&nbsp;Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.<blockquote>食品药品监督管理局授权默克(MRK)的抗病毒新冠药物莫努匹拉韦。但默克股票仍面临压力。</blockquote> The FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.<blockquote>FDA授权Ridgeback Biotherapeutics合作的药丸在其他选择不可用或不合适时紧急使用。辉瑞(PFE)的两片疗法Paxlovid也获得了授权。Paxlovid在临床测试中被证明更有效。此外，molnupiravir具有癌症风险，并可能导致未出生儿童的出生缺陷。</blockquote> Merck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.<blockquote>当患者在症状出现后五天内开始治疗时，默克公司的molnupiravir将与Covid相关的住院或死亡风险降低了30%。对于症状出现后三天内开始治疗的患者，Paxlovid将相同的风险降低了89%。</blockquote> Merck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.<blockquote>默克股价远低于11月份达到的高点。乐观的是，该公司超出了第三季度的预期，并提供了乐观的2021年前景，其中不包括抗病毒药物的潜在影响。Molnupiravir在英国和日本也被允许。</blockquote> Merck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.<blockquote>默沙东预计今年将生产1000万个疗程的molnupiravir，2022年至少生产2000万个疗程。它与包括美国在内的全球30多个国家签订了供应协议。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售额最高</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益增长28%至每股1.75美元，销售额飙升20%至131.5亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导欧加农（OGN）分拆。该制药公司将全年调整后利润预期上调至每股5.65美元至5.70美元，销售额为474亿美元至479亿美元。两项指标均超出预期。而且它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物Keytruda。Keytruda占第三季度总销售额的三分之一以上。Keytruda销售额增长22%，达到45.3亿美元。其人乳头瘤病毒疫苗Gardasil的销售额飙升68%，达到19.9亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物Januvia的收入下降了1%，至13.4亿美元。默克公司报告称，由于新冠疫苗在美国占据优先地位，其肺炎疫苗Pneumovax 23的销量下降了26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合CAN SLIM投资规则，该规则建议投资者寻找近期季度增长率为20%-25%或更高的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.<blockquote>FactSet调查的分析师预计默克本季度每股收益为1.52美元，销售额为131.6亿美元。与去年同期相比，盈利将飙升约21%，销售额将增长5%以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标对默克有何影响？</blockquote> As Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至12月27日，默克股价年内小幅下跌。股价最近创下至少三年来的新高，但此后一直在下跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克的销售额增长了2.5%，达到479.9亿美元。这一增长率较2019年11%的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.<blockquote>分析师预计2021年销售额将小幅增长至484.4亿美元。收入预计将增长2.8%，达到每股5.82美元。此前，2020年将增长14%。</blockquote> The stock ranks 6th by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业中的综合评级排名第六。由33家公司组成的医德药品集团在《投资者商报》追踪的197家集团中排名第51位。</blockquote> Technical Analysis Of The Pharmaceutical Company<blockquote>制药公司的技术分析</blockquote> Merck stock has a&nbsp;Composite Rating&nbsp;of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.<blockquote>默克股票的综合评级为81分（满分为99分）。CR是衡量股票过去12个月关键增长指标的指标。这使得默克股票在所有股票中排名前19%，无论行业类别如何。</blockquote> Shares also have a&nbsp;Relative Strength Rating&nbsp;of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.<blockquote>股票的相对强度评级也为57，反映了默克股票12个月的表现。这意味着该医药股的业绩排名低于所有股票的前三分之一。</blockquote> It's also key to watch chart patterns. Merck stock broke out of a&nbsp;flat base&nbsp;with abuy point&nbsp;at 79.33 on Oct. 1, according to&nbsp;MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are&nbsp;encouraged to sell&nbsp;when a stock is 7%-8% below its entry.<blockquote>观察图表模式也很关键。根据MarketSmith.com的数据，默克股价在10月1日突破了一个平盘，买入点为79.33点。但股价较11月30日入场时下跌了7%。这触发了卖出信号。当股票比进场价低7%-8%时，鼓励投资者卖出。</blockquote> Merck stock also recently undercut its&nbsp;50-day&nbsp;and&nbsp;200-day&nbsp;moving averages. Both are sell signals.<blockquote>默克股票最近也跌破了50日和200日移动平均线。两者都是卖出信号。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠协议</blockquote> Merck's molnupiravir is now authorized in the U.S., U.K. and Japan.<blockquote>默克公司的molnupiravir现已在美国、英国和日本获得授权。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药公司（AVIR）和Enanta制药(ENTA)正在研究口服新冠药物。罗氏(RHHBY)最近退出了与Atea的Covid抗病毒药物交易。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析师表示，与抗体药物相比，这些药物可能为新冠病毒的非住院治疗提供更容易的途径再生元制药（REGN），礼来公司（LLY）及维尔生物技术（来）。抗体药物必须由卫生保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心莫努匹拉韦的作用方式可能会给未出生婴儿的DNA带来突变。因此，FDA顾问对是否推荐孕妇使用它犹豫不决。</blockquote> Bearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and&nbsp;Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.<blockquote>悲观的是，FDA暂停了一项测试艾滋病毒预防药物islatravir的研究。一些患者显示关键免疫细胞减少。默克和吉利德科学（GILD）也决定停止在HIV患者中测试islatravir和吉利德的lenacapavir的一种方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克最近也完成了对Acceleron的收购。</blockquote> In early March, President Joe Biden announced Merck would helpJohnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克公司将提供帮助强生公司(JNJ)生产其新冠疫苗。默克公司将从生物医学高级研究与发展局获得2.688亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据CAN SLIM投资规则，不，默克股票目前不值得买入。股价已经反复突破了之前的突破，并引发了多个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利都可能低于预期。预计本季度的销售额不会达到这一目标。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大型股票可以在不实现大幅增长的情况下增加涨幅。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220\">Investors</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481741","content_text":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.\nMerck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.\nMerck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.\nMerck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.\nThe stock ranks 6th by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.\nTechnical Analysis Of The Pharmaceutical Company\nMerck stock has a Composite Rating of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.\nShares also have a Relative Strength Rating of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.\nIt's also key to watch chart patterns. Merck stock broke out of a flat base with abuy point at 79.33 on Oct. 1, according to MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are encouraged to sell when a stock is 7%-8% below its entry.\nMerck stock also recently undercut its 50-day and 200-day moving averages. Both are sell signals.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.S., U.K. and Japan.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nBearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would helpJohnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2637,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696127332"}